Mesenchymal Stromal Cells Prevent Allostimulation in Vivo and Control Checkpoints of Th1 Priming: Migration of Human DC to Lymph Nodes and NK Cell Activation

Stem Cells

Volumn 33, Issue 10, 2015, Pages 3087-3099

  Consentius, C ^a   Akyuz L ^a   Schmidt Lucke, J A ^b   Tschope C ^a   Pinzur, L ^c   Ofir, R ^c   Reinke, P ^a   Volk, H D ^a   Juelke, K ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Franziskus Hospital   (Germany)

^c PLURISTEM THERAPEUTICS INC   (Israel)

Author keywords

IL 10; Immunomodulation; Mesenchymal stromal cells; Myeloid dendritic cells; Natural killer cells; Th1 priming

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR7; GAMMA INTERFERON; HLA DR ANTIGEN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN;

ARTICLE; CELL ACTIVATION; CELL MIGRATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CRITICAL LIMB ISCHEMIA; CYTOKINE PRODUCTION; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; INTERFERON PRODUCTION; LYMPH NODE; MAJOR HISTOCOMPATIBILITY COMPLEX; MESENCHYMAL STROMA CELL; MYELOID DENDRITIC CELL; NATURAL KILLER CELL; PHENOTYPE; TH1 CELL; BONE MARROW CELL; CELL COMMUNICATION; CELL DIFFERENTIATION; COCULTURE; CYTOLOGY; FEMALE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PLACENTA; PREGNANCY;

CELL COMMUNICATION; CELL DIFFERENTIATION; COCULTURE TECHNIQUES; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNOMODULATION; INTERFERON-GAMMA; INTERLEUKIN-10; KILLER CELLS, NATURAL; LYMPH NODES; LYMPHOCYTE ACTIVATION; MESENCHYMAL STROMAL CELLS; MYELOID CELLS; PLACENTA; PREGNANCY; TH1 CELLS;

EID: 84942312853     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.2104     Document Type: Article

References (76)

1. Friedenstein AJ, Deriglasova UF, Kulagina NN, et al., Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol 1974; 2: 83-92.
2. Pittenger MF, Mackay AM, Beck SC, et al., Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143-147.
3. Uccelli A, Moretta L, Pistoia V,. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008; 8: 726-736.
4. Le Blanc K, Mougiakakos D,. Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol 2012; 12: 383-396.
5. Spaggiari GM, Moretta L,. Cellular and molecular interactions of mesenchymal stem cells in innate immunity. Immunol Cell Biol 2013; 91: 27-31.
6. Connick P, Kolappan M, Crawley C, et al., Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: An open-label phase 2a proof-of-concept study. Lancet Neurol 2012; 11: 150-156.
7. Duijvestein M, Vos ACW, Roelofs H, et al., Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: Results of a phase I study. Gut 2010; 59: 1662-1669.
8. Pileggi A, Xu X, Tan J, et al., Mesenchymal stromal (stem) cells to improve solid organ transplant outcome: Lessons from the initial clinical trials. Curr Opin Organ Transplant 2013; 18: 672-681.
9. Ringden O, Le Blanc K,. Mesenchymal stem cells for treatment of acute and chronic graft-versus-host disease, tissue toxicity and hemorrhages. Best Pract Res Clin Haematol 2011; 24: 65-72.
10. Kim N, Im K-I, Lim J-Y, et al., Mesenchymal stem cells for the treatment and prevention of graft-versus-host disease: Experiments and practice. Ann Hematol 2013; 92: 1295-1308.
11. Neef K, Choi Y-H, Weichel A, et al., The influence of cardiovascular risk factors on bone marrow mesenchymal stromal cell fitness. Cytotherapy 2012; 14: 670-678.
12. Stamm C, Nasseri B, Drews T, et al., Cardiac cell therapy: A realistic concept for elderly patients? Exp Gerontol 2008; 43: 679-690.
13. Crop MJ, Baan CC, Korevaar SS, et al., Donor-derived mesenchymal stem cells suppress alloreactivity of kidney transplant patients. Transplantation 2009; 87: 896-906.
14. Luyckx A, Somer L De, Jacobs S, et al., Oct4-negative multipotent adult progenitor cells and mesenchymal stem cells as regulators of T-cell alloreactivity in mice. Immunol Lett 2011; 137: 78-81.
15. Seifert M, Stolk M, Polenz D, et al., Detrimental effects of rat mesenchymal stromal cell pre-treatment in a model of acute kidney rejection. Front Immunol 2012; 3: 202.
16. Roemeling-van Rhijn M, Reinders ME, Franquesa M, et al., Human allogeneic bone marrow and adipose tissue derived mesenchymal stromal cells induce CD8+ cytotoxic T cell reactivity. J Stem Cell Res Ther 2013; 3 (suppl 6): 004.
17. Casiraghi F, Remuzzi G, Perico N,. Mesenchymal stromal cells to promote kidney transplantation tolerance. Curr Opin Organ Transplant 2014; 19: 47-53.
18. Schu S, Nosov M, O'Flynn L, et al., Immunogenicity of allogeneic mesenchymal stem cells. J Cell Mol Med 2012; 16: 2094-2103.
19. Griffin MD, Ryan AE, Alagesan S, et al., Anti-donor immune responses elicited by allogeneic mesenchymal stem cells: What have we learned so far? Immunol Cell Biol 2013; 91: 40-51.
20. Nauta AJ, Westerhuis G, Kruisselbrink AB, et al., Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 2006; 108: 2114-2120.
21. Morandi B, Bougras G, Muller WA, et al., NK cells of human secondary lymphoid tissues enhance T cell polarization via IFN-gamma secretion. Eur J Immunol 2006; 36: 2394-2400.
22. Martín-Fontecha A, Thomsen LL, Brett S, et al., Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol 2004; 5: 1260-1265.
23. Ing R, Stevenson MM,. Dendritic cell and NK cell reciprocal cross talk promotes gamma interferon-dependent immunity to blood-stage Plasmodium chabaudi AS infection in mice. Infect Immun 2009; 77: 770-782.
24. Banchereau J, Steinman RM,. Dendritic cells and the control of immunity. Nature 1998; 392: 245-252.
25. Mailliard RB, Son Y-I, Redlinger R, et al., Dendritic cells mediate NK cell help for Th1 and CTL responses: Two-signal requirement for the induction of NK cell helper function. J Immunol 2003; 171: 2366-2373.
26. Kaliński P, Hilkens CM, Wierenga EA, et al., T-cell priming by type-1 and type-2 polarized dendritic cells: The concept of a third signal. Immunol Today 1999; 20: 561-567.
27. Moser M, Murphy KM,. Dendritic cell regulation of TH1-TH2 development. Nat Immunol 2000; 1: 199-205.
28. Sotiropoulou PA, Perez SA, Gritzapis AD, et al., Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 2006; 24: 74-85.
29. Nauta AJ, Kruisselbrink AB, Lurvink E, et al., Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J Immunol 2006; 177: 2080-2087.
30. Nicola M Di, Carlo-Stella C, Magni M, et al., Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99: 3838-3843.
31. Walzer T, Dalod M, Vivier E, et al., Natural killer cell-dendritic cell crosstalk in the initiation of immune responses. Expert Opin Biol Ther 2005; 5 (suppl 1): S49-59.
32. Moretta A,. Natural killer cells and dendritic cells: Rendezvous in abused tissues. Nat Rev Immunol 2002; 2: 957-964.
33. Ferlazzo G, Tsang ML, Moretta L, et al., Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med 2002; 195: 343-351.
34. Moretta L, Ferlazzo G, Bottino C, et al., Effector and regulatory events during natural killer-dendritic cell interactions. Immunol Rev 2006; 214: 219-228.
35. Ferlazzo G, Thomas D, Lin S-L, et al., The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J Immunol 2004; 172: 1455-1462.
36. Cooper MA, Fehniger TA, Turner SC, et al., Human natural killer cells: A unique innate immunoregulatory role for the CD56(bright) subset. Blood 2001; 97: 3146-3151.
37. Ferlazzo G, Pack M, Thomas D, et al., Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. Proc Natl Acad Sci USA 2004; 101: 16606-16611.
38. Trinchieri G,. Biology of natural killer cells. Adv Immunol 1989; 47: 187-376.
39. Gerosa F, Baldani-Guerra B, Nisii C, et al., Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 2002; 195: 327-333.
40. Vitale M, Chiesa M,. Della, Carlomagno S, et al., The small subset of CD56brightCD16- natural killer cells is selectively responsible for both cell proliferation and interferon-gamma production upon interaction with dendritic cells. Eur J Immunol 2004; 34: 1715-1722.
41. Cooper MA, Fehniger TA, Caligiuri MA,. The biology of human natural killer-cell subsets. Trends Immunol 2001; 22: 633-640.
42. Macagno A, Napolitani G, Lanzavecchia A, et al., Duration, combination and timing: The signal integration model of dendritic cell activation. Trends Immunol 2007; 28: 227-233.
43. Moser M,. Dendritic cells in immunity and tolerance-do they display opposite functions? Immunity 2003; 19: 5-8.
44. Djouad F, Charbonnier L-M, Bouffi C, et al., Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells 2007; 25: 2025-2032.
45. Spaggiari GM, Abdelrazik H, Becchetti F, et al., MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: Central role of MSC-derived prostaglandin E2. Blood 2009; 113: 6576-6583.
46. Jiang X-X, Zhang Y, Liu B, et al., Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005; 105: 4120-4126.
47. Melief SM, Geutskens SB, Fibbe WE, et al., Multipotent stromal cells skew monocytes towards an anti-inflammatory interleukin-10-producing phenotype by production of interleukin-6. Haematologica 2013; 98: 888-895.
48. Varol C, Landsman L, Fogg DK, et al., Monocytes give rise to mucosal, but not splenic, conventional dendritic cells. J Exp Med 2007; 204: 171-180.
49. Liu K, Victora GD, Schwickert TA, et al., In vivo analysis of dendritic cell development and homeostasis. Science 2009; 324: 392-397.
50. Aggarwal S, Pittenger MF,. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105: 1815-1822.
51. Prather WR, Toren A, Meiron M, et al., The role of placental-derived adherent stromal cell (PLX-PAD) in the treatment of critical limb ischemia. Cytotherapy 2009; 11: 427-434.
52. Juelke K, Killig M, Luetke-Eversloh M, et al., CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells. Blood 2010; 116: 1299-1307.
53. Betts MR, Brenchley JM, Price DA, et al., Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003; 281: 65-78.
54. Bestard O, Crespo E, Stein M, et al., Cross-validation of IFN-γ Elispot assay for measuring alloreactive memory/effector T cell responses in renal transplant recipients. Am J Transplant 2013; 13: 1880-1890.
55. Ohl L, Mohaupt M, Czeloth N, et al., CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions. Immunity 2004; 21: 279-288.
56. Napolitani G, Rinaldi A, Bertoni F, et al., Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 2005; 6: 769-776.
57. Zhang W, Ge W, Li C, et al., Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev 2004; 13: 263-271.
58. Bryceson YT, March ME, Ljunggren H-G, et al., Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 2006; 107: 159-166.
59. Prather WR, Toren A, Meiron M,. Placental-derived and expanded mesenchymal stromal cells (PLX-I) to enhance the engraftment of hematopoietic stem cells derived from umbilical cord blood. Expert Opin Biol Ther 2008; 8: 1241-1250.
60. Roy R, Brodarac A, Kukucka M, et al., Cardioprotection by placenta-derived stromal cells in a murine myocardial infarction model. J Surg Res 2013; 185: 70-83.
61. Stubbendorff M, Deuse T, Hua X, et al., Immunological properties of extraembryonic human mesenchymal stromal cells derived from gestational tissue. Stem Cells Dev 2013; 22: 2619-2629.
62. Bestard O, Cruzado JM, Lucia M, et al., Prospective assessment of antidonor cellular alloreactivity is a tool for guidance of immunosuppression in kidney transplantation. Kidney Int 2013; 84: 1226-1236.
63. Chiesa S, Morbelli S, Morando S, et al., Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells. Proc Natl Acad Sci USA 2011; 108: 17384-17389.
64. English K, Barry FP, Mahon BP,. Murine mesenchymal stem cells suppress dendritic cell migration, maturation and antigen presentation. Immunol Lett 2008; 115: 50-58.
65. Zhang W, Ge W, Li C, et al., Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev 2004; 13: 263-271.
66. Li Y-P, Paczesny S, Lauret E, et al., Human mesenchymal stem cells license adult CD34+ hemopoietic progenitor cells to differentiate into regulatory dendritic cells through activation of the notch pathway. J Immunol 2008; 180: 1598-1608.
67. Levings MK, Gregori S, Tresoldi E, et al., Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells. Blood 2005; 105: 1162-1169.
68. Svajger U, Rozman P,. Tolerogenic dendritic cells: Molecular and cellular mechanisms in transplantation. J Leukoc Biol 2014; 95: 53-69.
69. Moore KW, de Waal Malefyt R, Coffman RL, et al., Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19: 683-765.
70. D'Andrea A, Aste-Amezaga M, Valiante NM, et al., Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 1993; 178: 1041-1048.
71. Arend WP,. Interleukin 1 receptor antagonist. A new member of the interleukin 1 family. J Clin Invest 1991; 88: 1445-1451.
72. Hunter CA, Chizzonite R, Remington JS,. IL-1 beta is required for IL-12 to induce production of IFN-gamma by NK cells. A role for IL-1 beta in the T cell-independent mechanism of resistance against intracellular pathogens. J Immunol 1995; 155: 4347-4354.
73. Ryan JM, Barry FP, Murphy JM, et al., Mesenchymal stem cells avoid allogeneic rejection. J Inflamm (Lond) 2005; 2: 8.
74. Waterman RS, Tomchuck SL, Henkle SL, et al., A new mesenchymal stem cell (MSC) paradigm: Polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS One 2010; 5: e10088.
75. Liu X, Qu X, Chen Y, et al., Mesenchymal stem/stromal cells induce the generation of novel IL-10-dependent regulatory dendritic cells by SOCS3 activation. J Immunol 2012; 189: 1182-1192.
76. Ortiz LA, Dutreil M, Fattman C, et al., Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci USA 2007; 104: 11002-11007.